A new method to prevent blood clots in patients with specific autoimmune antibodies
Official title: Introducing NanoProTEN, a novel approach for anticoagulation in patients with prothrombotic autoantibodies
Funded at Saint Louis University · NIH-11063267 · Data updated 2026-11-12
This study is testing a new treatment called NanoProTEN that aims to help people with antiphospholipid syndrome reduce their risk of blood clots, especially for those who haven't had success with current medications.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | April 15, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $189,375 |
| NIH project number | 5R21HL173848-02 |
| Project ID | NIH-11063267 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with antiphospholipid syndrome or those with prothrombotic autoantibodies who have had limited success with existing anticoagulant therapies.
✕Less likely to help
Patients without autoimmune disorders or those who do not have prothrombotic autoantibodies may not benefit from this research.
What this research studies
This research focuses on developing a novel technology called NanoProTEN, which aims to reduce the risk of blood clots in patients with prothrombotic autoantibodies, particularly those with antiphospholipid syndrome. The approach involves targeting specific domains of coagulation factors to better control blood clot formation compared to existing anticoagulant medications. By using an in vitro selection process, researchers have identified a promising nanobody that could improve treatment outcomes for patients who do not respond well to current therapies. The study will investigate the biochemical properties of this nanobody to ensure its effectiveness and safety.
Why it matters
Potential benefit: If successful, this research could provide a more effective anticoagulation treatment for patients with autoimmune conditions that predispose them to blood clots.
How similar studies have gone: While this approach is innovative, it builds on existing knowledge of coagulation factors, and preliminary studies have shown promise in similar methodologies.
Where this research is happening
-
Saint Louis University
Saint Louis, United States Active
Researchers
- Principal investigator: Pozzi, Nicola — Saint Louis University
- Study coordinator: Pozzi, Nicola
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.